Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia.

Front Oncol · 2020 · PMC7921696 · PMID 33665170

Europe PMC DOI

hedged sentence

0.0980

closest p · 2.0× alpha

0.0980

boldest claim

The sentences

did not reach statistical significancep = 0.098so close (0.05 < p ≤ 0.1)

The overall thrombosis annual incidence rate was 3.09% (95% CI 1.22–4.96) in ruxolitinib treated patients as compared with 5.51% (95% CI 3.72–7.30) in the BAT group, corresponding to a incidence rate ratio of 0.56 (95% confidence interval 0.28–1.11), which did not reach statistical significance (p = 0.098) ( 23 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.